CO6551670A2 - Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo - Google Patents

Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo

Info

Publication number
CO6551670A2
CO6551670A2 CO12070154A CO12070154A CO6551670A2 CO 6551670 A2 CO6551670 A2 CO 6551670A2 CO 12070154 A CO12070154 A CO 12070154A CO 12070154 A CO12070154 A CO 12070154A CO 6551670 A2 CO6551670 A2 CO 6551670A2
Authority
CO
Colombia
Prior art keywords
complex
botulinum toxin
botulin
free
purifying
Prior art date
Application number
CO12070154A
Other languages
English (en)
Inventor
L Curtis Ruegg
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43879799&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6551670(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO6551670A2 publication Critical patent/CO6551670A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a los sistemas y métodos para purificar una toxina botulínica libre de complejo. En una realización, el método incluye purificar la toxina botulínica libre de complejo en estado crudo para obtener una toxina botulínica libre de complejo purificada. En esta realización, el método comprende cargar una columna de intercambio aniónico con la toxina botulinica libre de complejo en estado crudo para capturar la toxina botulínica libre de complejo en la columna de intercambio aniónico; eluir la toxina botulínica libre de complejo con un buffer para dar u eluente que incluya la toxina botulínica libre de complejo; cargar una columna de intercambio catiónico con el eluente del intercambio aniónico a la columna para permitir la captura de la toxina botulínica libre de complejo; y eluir la toxina botulínica libre de complejo con otro buffer para dar un eluente, obteniendo a partir de allí una toxina botulinica libre de complejo purificada.
CO12070154A 2009-10-21 2012-04-30 Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo CO6551670A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25381009P 2009-10-21 2009-10-21

Publications (1)

Publication Number Publication Date
CO6551670A2 true CO6551670A2 (es) 2012-10-31

Family

ID=43879799

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12070154A CO6551670A2 (es) 2009-10-21 2012-04-30 Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo

Country Status (23)

Country Link
US (5) US20110092682A1 (es)
EP (1) EP2490986B2 (es)
JP (1) JP5951490B2 (es)
KR (1) KR101819129B1 (es)
CN (2) CN102666396B (es)
AU (1) AU2010310749B2 (es)
BR (1) BR112012009227A2 (es)
CA (1) CA2773396C (es)
CO (1) CO6551670A2 (es)
CY (1) CY1120908T1 (es)
DK (1) DK2490986T4 (es)
ES (1) ES2688065T3 (es)
HK (2) HK1175453A1 (es)
HR (1) HRP20181869T1 (es)
HU (1) HUE041599T2 (es)
IL (2) IL218532A (es)
LT (1) LT2490986T (es)
MX (3) MX2012004703A (es)
PL (1) PL2490986T3 (es)
PT (1) PT2490986T (es)
RS (1) RS58006B1 (es)
SI (1) SI2490986T1 (es)
WO (1) WO2011050072A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3332805T3 (da) 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
MX2012004703A (es) * 2009-10-21 2012-06-08 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3901163A4 (en) * 2018-12-21 2022-10-05 The Research Foundation for Microbial Diseases of Osaka University PROCESS FOR THE PRODUCTION OF BOTULINUM TOXIN
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR20230009178A (ko) * 2021-07-08 2023-01-17 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US796419A (en) 1904-07-18 1905-08-08 Carl Halbig Doll-head.
SE303567B (es) * 1959-02-17 1968-09-02 Behringwerke Ag
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
ES2617692T3 (es) * 2000-07-21 2017-06-19 Revance Therapeutics, Inc. Sistemas de transporte de agentes biológicos de múltiples componentes
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB2386246B (en) 2001-11-01 2005-06-29 Marconi Applied Techn Ltd Electron beam tube apparatus
ATE494367T1 (de) * 2002-12-18 2011-01-15 Hoffmann La Roche Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
KR100498964B1 (ko) 2003-03-05 2005-07-01 삼성전자주식회사 이동단말에서의 전자파 흡수율 제어 방법 및 장치
AU2003271835A1 (en) * 2003-06-06 2005-01-04 Avecia Limited Process for the separation of proteins
WO2006096164A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
JP2007535911A (ja) * 2003-12-30 2007-12-13 バハラ バイオテック インターナショナル リミテッド 組換えタンパク質の製造及び精製方法
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
CA3031270A1 (en) * 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
EP1729821B1 (en) * 2004-03-03 2013-07-17 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4879978B2 (ja) * 2005-06-17 2012-02-22 メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー 生物活性化合物を発酵生産するための装置及び方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
ES2537579T3 (es) * 2006-10-27 2015-06-09 The Chemo-Sero-Therapeutic Research Institute Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante
CN100588706C (zh) * 2007-04-06 2010-02-10 常州千红生化制药股份有限公司 纯化弹性蛋白酶的方法
MX2009012570A (es) * 2007-06-01 2010-03-15 Merz Pharma Gmbh & Co Kgaa Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
DK3332805T3 (da) * 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
MX2012004703A (es) † 2009-10-21 2012-06-08 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
US8440104B2 (en) * 2009-10-21 2013-05-14 General Electric Company Kimzeyite garnet phosphors
WO2013181576A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods of evaluating and making biologics
US20140120077A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
JP6955491B2 (ja) * 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.

Also Published As

Publication number Publication date
US9469849B2 (en) 2016-10-18
PT2490986T (pt) 2018-11-13
KR20120099431A (ko) 2012-09-10
DK2490986T4 (da) 2024-06-17
US20170029795A1 (en) 2017-02-02
WO2011050072A1 (en) 2011-04-28
MX2012004703A (es) 2012-06-08
SI2490986T1 (sl) 2018-12-31
KR101819129B1 (ko) 2018-02-28
US20120196349A1 (en) 2012-08-02
US11466262B2 (en) 2022-10-11
LT2490986T (lt) 2018-11-26
HK1215951A1 (zh) 2016-09-30
CY1120908T1 (el) 2019-12-11
AU2010310749B2 (en) 2016-02-11
HK1175453A1 (en) 2013-07-05
EP2490986A1 (en) 2012-08-29
HRP20181869T1 (hr) 2019-01-11
US20110092682A1 (en) 2011-04-21
JP2013508388A (ja) 2013-03-07
AU2010310749A1 (en) 2012-03-29
EP2490986B2 (en) 2024-04-24
MX2019006519A (es) 2019-09-18
IL218532A (en) 2016-10-31
JP5951490B2 (ja) 2016-07-13
CN102666396B (zh) 2015-05-13
RS58006B1 (sr) 2019-02-28
IL248486A0 (en) 2016-12-29
CA2773396A1 (en) 2011-04-28
EP2490986B1 (en) 2018-08-08
BR112012009227A2 (pt) 2016-08-23
ES2688065T3 (es) 2018-10-30
IL218532A0 (en) 2012-07-31
US20200277591A1 (en) 2020-09-03
MX365496B (es) 2019-06-05
CN104961812A (zh) 2015-10-07
US20150322419A1 (en) 2015-11-12
DK2490986T3 (en) 2018-11-05
CA2773396C (en) 2020-12-15
CN102666396A (zh) 2012-09-12
EP2490986A4 (en) 2013-11-13
CN104961812B (zh) 2019-08-20
HUE041599T2 (hu) 2019-05-28
PL2490986T3 (pl) 2019-03-29

Similar Documents

Publication Publication Date Title
CO6551670A2 (es) Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo
SG11201706545VA (en) Systems, devices, and methods for eyebox expansion in wearable heads-up displays
BR112013000623A2 (pt) purificação de proteína.
MX2018007134A (es) Metodo y dispositivo de ayuda al estacionamiento.
BR112013032215A2 (pt) método e sistema para processamento de consultas de saldo de contas financeiras
BR112015031196A2 (pt) “processo de purificação de anticorpo monoclonal”
GB2488298A (en) System and method for facilitating affiliate marketing relationships
BR112013002334A2 (pt) método para purificar polipeptídeos ou imunoconjugados ativos.
BR112014007935A8 (pt) Sistema para criar um relatório em uma planilha e métodos para identificar relações entre tabelas em uma planilha
CL2014001984A1 (es) Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos.
AR069097A1 (es) Purificacion de anticuerpos por cromatografia de intercambio cationico
AR076137A1 (es) Modulo, sistema y metodo de interfaz.
BR112013018294A2 (pt) sistema e método para suportar jit em um sistema seguro com faixas de memórias alocadas randomicamente
AR090319A1 (es) Biorrefineria integrada
GB201214701D0 (en) Method and device for labeling touch region of a display device
WO2013147955A3 (en) Method and system to provide a scroll map
EP3076170A4 (en) Solid-phase carrier, production method for solid-phase carrier, carrier for affinity refining, production method for filler for affinity chromatography, filler for affinity chromatography, chromatography column, and refining method
BR112018000464A2 (pt) sistema de armazenamento gasoso, métodos para produzir e utilizá-lo
CO2019003427A2 (es) Métodos para mejorar el resabio de bebidas alcohólicas usando alulosa
AR094756A1 (es) Método para reducir el consumo de energía por acoplamiento térmico
BR112019001494A2 (pt) método implementado por computador e sistema para determinar um desenho melhorado para uma lente de óculos progessiva, método para fabricação de uma lente progressiva e programa de computador não transitório
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
BR112013000258B8 (pt) Processo para preparação de uma estrutura laminada
AR087103A1 (es) Tecnologia de simulacion integrada
TW201614621A (en) Defect detecting method and display panel

Legal Events

Date Code Title Description
FA Application withdrawn